ストックスクリーナーアプリを入手
1.60
4.76%
-0.08
プレマーケット:
1.60
前日終値:
$1.68
開ける：
$1.67
24時間の取引高:
2.16M
Relative Volume:
1.48
時価総額：
$334.28M
収益：
$889.00K
当期純損益:
$-156.28M
株価収益率:
-3.0378
EPS:
-0.5267
ネットキャッシュフロー:
$-150.06M
1週間 パフォーマンス:
-16.23%
1か月 パフォーマンス:
-7.51%
6か月 パフォーマンス:
-12.57%
1年 パフォーマンス:
-38.93%
1日の値動き範囲:
$1.565
$1.69
1週間の範囲:
$1.565
$1.9094
52週間の値動き範囲:
$1.30
$3.4799
Prokidney Corp Stock (PROK) Company Profile
Compare PROK vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.60 | 334.28M | 889.00K | -156.28M | -150.06M | -0.5267 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2025-06-30 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-09-30 | 開始されました | JP Morgan | Neutral |
| 2024-09-10 | 開始されました | Guggenheim | Buy |
| 2024-03-07 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-01-02 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-07-25 | 開始されました | BTIG Research | Buy |
| 2022-12-21 | 開始されました | Jefferies | Buy |
| 2022-11-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 開始されました | UBS | Buy |
| 2022-10-14 | 開始されました | Citigroup | Buy |
| 2022-09-23 | 開始されました | BofA Securities | Buy |
| 2022-09-02 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Prokidney Corp (PROK) 最新ニュース
ProKidney (NASDAQ:PROK) Stock Price Down 7.6%Should You Sell? - MarketBeat
ProKidney (NASDAQ:PROK) Trading 6% HigherStill a Buy? - MarketBeat
ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict - Yahoo Finance
ProKidney (NASDAQ:PROK) Stock Price Up 7.6%Should You Buy? - MarketBeat
ProKidney Corp. (PROK) Jumps 7.55% as Clinical-Stage Kidney Specialist ReboundsOn Balance Volume - dars.gov.et
3 Promising Penny Stocks With Market Caps Larger Than $200M - simplywall.st
SAB BIO to Participate in Upcoming Investor Conferences - Investing News Network
Keep An Eye On ProKidney As Insider Stock Selling Hits US$3.0m - 富途牛牛
ProKidney (PROK) EPS and Revenue: Headline Results Are Close to Consensus; Post-Earnings: The Stock Closes Near UnchangedBanking Earnings Report - vinanet.vn
ProKidney director Brian Pereira sells $1.07 million in shares By Investing.com - Investing.com Canada
ProKidney director Brian Pereira sells $1.07 million in shares - Investing.com
ProKidney (PROK) Quarter in Focus: The Available Figures Are Largely in Line; Post-Report: Shares Fall 4.05% in the Latest ReadingGuidance Update - vinanet.vn
Brian Jg Pereira Sells 229,338 Shares of ProKidney (NASDAQ:PROK) Stock - MarketBeat
ProKidney (NASDAQ:PROK) Director Sells 222,949 Shares - MarketBeat
Prokidney Insider Sold Shares Worth $1,067,773, According to a Recent SEC Filing - marketscreener.com
ProKidney Director Sold Shares Worth Over $1.0M - TradingView
ProKidney (PROK) director sells 757K shares over 3 days - Stock Titan
ProKidney (PROK) Close: Ends Higher by 3.99% at $1.44 at the Close; Immediate View: Support at $1.37 and Resistance at $1.51 Frame the Range under the Current SnapshotOBV Divergence - vinanet.vn
ProKidney (NASDAQ: PROK) director plans new restricted stock sale - Stock Titan
ProKidney (NASDAQ: PROK) director plans sale after trust offloads 229K - Stock Titan
ProKidney (PROK) Latest Reading: Moves 0.71% Lower to $1.39 in the Current Update; Range Context: the Near-Term Reference Band Stretches From $1.32 to $1.46 in Latest TradingFibonacci Entry Signals - vinanet.vn
ProKidney (PROK) Earnings Comparison: Results Show Limited Variance From Forecasts in the Latest Session; Market Follow-Through: The Market Price Declines 0.36% on the DayPost-Earnings Reaction - vinanet.vn
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) (PROK) - Seeking Alpha
PROK Q1 2026 Earnings: Narrow EPS Beat Overshadowed by 5% Stock DeclineEarnings Volatility Report - vinanet.vn
What is HC Wainwright's Estimate for ProKidney Q3 Earnings? - MarketBeat
ProKidney Corp. (PROK) Slides 9.3% to $1.46 as Key Support Level Comes into FocusVolume Breakout Ideas - dars.gov.et
Morgan Stanley (PROK) filings show ProKidney stake at 4.7% and below 5% level - Stock Titan
ProKidney (PROK) Gets a Buy from Guggenheim - The Globe and Mail
ProKidney FY2030 EPS Estimate Decreased by HC Wainwright - MarketBeat
ProKidney reports larger second-quarter loss as key clinical trial expenses mount - Winston-Salem Journal
ProKidney earnings missed, revenue topped estimates By Investing.com - Investing.com Nigeria
ProKidney earnings missed, revenue topped estimates - Investing.com
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
ProKidney completes Phase 3 PROACT 1 accelerated approval enrollment - scanx.trade
ProKidney (NASDAQ:PROK) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
ProKidney reports Q2 revenue of $150,000 as PROACT 1 advances - Quiver Quantitative
Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise - TradingView
PROK: Completed key Phase 3 trial enrollment; cash supports operations into mid-2027 - TradingView
ProKidney Corp. (NASDAQ: PROK) warns on cash runway after $89M H1 loss - Stock Titan
ProKidney Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights - Yahoo Finance
ProKidney Corp (PROK) Stock News Today - TradingKey
PROK Q1 2026 Earnings: Slight EPS Beat Signals Discipline as Clinical Pipeline Drives ValueEarnings Call Transcript - careplusvn.com
ProKidney Corp. (PROK) director converts paired units into Class A stock - Stock Titan
3 Promising Penny Stocks With Market Caps Under $500M - simplywall.st
PROK Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
ProKidney (PROK) to Release Quarterly Earnings on Tuesday - marketbeat.com
ProKidney Corp. Revenue Breakdown – NASDAQ:PROK - TradingView
ProKidney Corp (PROK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Prokidney Corp (PROK) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):